Gonal-F Articles

Merck KGaA returns to profit in 4th-qtr 2009, as revenues rise, but disappoints

23 February 2010

Merck KGaA 3rd quarter 2009 revenue up 2.7% but pretax profits plunge 31%

26 October 2009

Merck KGaA's 1st-qtr profit tumbles 76.3% to 56.7M euros on lower liquid crystal sales

27 April 2009

Merck KGaA sees 2008 loss on acquisition costs and crystals, but pharma good

23 February 2009

Merck KGaA submits sNDA in Japan for Gonal-f

3 November 2008

Germany's Merck KGaA profit rockets in 3rd qtr on recovery from Serono acquisition

3 November 2008

Merck Serono to grow Japanese business

4 August 2008

Merck KGaA's 2nd-qtr results strong on revenue from Serono acquisition

28 July 2008

Merck KGaA's swings to profit of 239.1M euros as sales rise 8.3% on Erbitux and Rebif

5 May 2008

Merck KGaA revenues, core EPS rocket but 4th-qtr operating results slump 21%

25 February 2008

EC approves Merck KGaA's Pergoveris

9 July 2007

Merck KGaA posts 49% net profit rise for 2006, with revenues up 8.5%

12 March 2007

Serono's 3rd-qtr 2006 sales rise 8.4% on Rebif

30 October 2006

Serono ready for acquisition trial as it turns in a first-quarter profit

1 May 2006

Serono 4th qtr shows profit but disappoints

13 February 2006

Serono's Gonal-f approved in Japan

30 January 2006

UPDATE: Serono tops forecasts as EPS rockets 54%

1 November 2004

Serono sees 3rd-qtr net income leaps 47%

1 November 2004

Expanded US use for Serono's Luveris

25 October 2004

Serono's 2nd-qtr net income jumps 26%

2 August 2004

Serono infertility APIs to be made in Spain

19 July 2004

FDA OKs Serono's Gonal-f RFF Pen

31 May 2004

Serono's 1st-qtr income rockets 76.4%

26 April 2004

Serono's Gonal-f pre-filled pen gets OK from EC

8 March 2004

Serono 2003 profits up 21.6%, beating forecasts; promises even more

9 February 2004

Ferring expands infertility portfolio by acquiring Novartis' Norprolac

5 January 2004

Serono beats expectations with 3rd-qtr 2003 net income up 48%

3 November 2003

Serono raises 2003 forecast; 2nd-qtr figs

4 August 2003

Serono

5 May 2003

Serono sees 15%-20% growth for 2003

10 February 2003

Ferring gets US OK for infertility drug

13 May 2002

Serono reports 10.4% 1st-qtr sales increase

29 April 2002

Funding and approving new drugs in Israel's NHI basket

18 February 2002

Serono's 2001 5.2% net income rise below consensus forecasts

18 February 2002

Serono reports disappointing sales

31 October 2001

Net income at Switzerland's Serono jumps 42.5% as Rebif growth continues

24 July 2001

Serono announces strategy for development at first R&D day

17 July 2001

PowderJect sets out strategy to become leading global vaccines player

5 July 2001

Serono/Alkermes to progress r-hFSH

17 May 2001

Serono makes strong start to 2001

2 May 2001

Profits at Switzerland's Serono jump 64.2% as royalty revenues rise

6 March 2001

Rebif pushes Serono sales up 16.2%

23 January 2001

Serono gets EU go-ahead for Luveris and Ovidrelle infertility drugs

5 December 2000

Serono third-quarter earnings leap 83%

24 October 2000

FDA grants first OK for Serono's Ovidrel

3 October 2000

Serono sees 2nd-qtr net income leap 60%

21 July 2000

PowderJect losses spark share fall despite Serono deal

15 June 2000

PowderJect gets L1 million from Serono

12 June 2000

Stock Commentary Europe

8 June 2000

New US marketing approvals granted for Serono's Gonal-F

7 June 2000

Ares-Serono 1sr qtr net income leaps 39.2%

28 April 2000

Serono "almost perfect biotech investment"

10 March 2000

Ares-Serono 1999 net income soars 141%, pipeline makes future look healthy

2 March 2000

Ares-Serono sales hit $1 billion mark

19 January 2000

EU approval for Ares-Serono's Gonal-F

1 July 1999

1st qtr net income up 111% at Ares-Serono

30 April 1999

Puregon Solution approved by EMEA

28 April 1999

CPMP backs superiority of Gonal-F

29 March 1999

Ares-Serono's earnings beat expectations

11 March 1999

Ares-Serono posts solid growth in 1998

19 January 1999

Sales Fall But Profits Rise At Ares-Serono

18 August 1998

Sales Fall But Profits Rise At Ares-Serono

16 April 1998

Ares-Serono Earnings Jump 64% For 1997

3 March 1998

Strong $ Hits Ares-Serono's European Growth

16 January 1998

FDA Clears rFSH Products From Serono, Akzo Nobel

9 October 1997

First Approval Of Geref As Therapeutic

9 October 1997

A Good Start To 1997 For Ares-Serono

5 May 1997

Ares-Serono Sales Growth Still Led By Infertility Products

27 January 1997

Record Number Of New Chemical Entities In 1996

20 January 1997

Strong Growth For Ares-Serono

11 November 1996

1st-Half Sales Rise 15% At Ares-Serono

2 September 1996

EMEA: Experiences Of The First Year

6 May 1996

EMEA 1995-95: A Crucial Period of Transition

25 March 1996

Ares-Serono" Good Sales Growth In 1995

5 February 1996

EMEA Reports Successes In Inaugural 1995

5 February 1996

Ares-Serono: Gonal-F news

18 December 1995

Ares-Serono's Net Income Makes Quarterly Increase

27 November 1995

New Challenges Facing EU Pharma Wholesalers

13 November 1995

First EMEA Approval Is For Serono's Gonal-F

30 October 1995

Ares-Serono Invests $25 million In Puerto Rican Plant

23 October 1995

ARES-SERONO WINS FSH PATENT DISPUTE

14 February 1994

ARES-SERONO FILES NDA

13 December 1993

ARES-SERONO WILL BENEFIT FROM MS MARKET

27 September 1993

ARES-SERONO PIPELINE OVERVIEW

31 May 1993

ARES-SERONO FILES NEW rFSH SUIT

26 April 1993

ARES-SERONO NETPROFITS LEAP 51%

15 March 1993

FIRST BIRTH USING SERONO'S r-hFSH

12 October 1992

SERONO ACHIEVES IVF SUCCESS WITH rhFSH

18 May 1992

Showing 1-88 of 88 articles

Go to beginningPrevious
  • 1
NextGo to end